Inside Precision Medicine examines the growing global burden of cancer and the emerging technologies reshaping how the disease is detected and treated. The article highlights the need for earlier, more personalized approaches to cancer screening as rates continue to rise worldwide.

The article explores how traditional cancer screening methods, often based primarily on age and population averages, may leave opportunities for earlier detection. It also highlights the growing role of advanced diagnostics, artificial intelligence, genomics, and other emerging technologies in identifying cancer risk and disease at earlier, more actionable stages.

PreOncology™ is featured in the article as part of this evolving approach to cancer detection. The PreOncology Platform™ combines personalized risk assessment, advanced diagnostics, and oncology expertise to help primary care physicians identify patients who may benefit from earlier and more comprehensive screening.

“The number of oncology cases is not declining, unlike cardiology and other conditions,” said Jose Barreau, MD, Founder and CEO of PreOncology, in the article. “Primary care doctors in particular can use help with these patients.” Dr. Barreau highlights the growing need for oncology expertise within primary care and the importance of helping physicians navigate increasingly complex cancer risk and screening data, including genetics, imaging, and emerging biomarkers.

As cancer incidence continues to increase globally, the article underscores the importance of moving beyond traditional screening models and exploring new strategies designed to detect cancer earlier, when more treatment options may be available.

Read the full article in Inside Precision Medicine.